Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Scleritis, Clinically Significant Macular Edema
Interventions: H.P. ACTHAR SUBCUTANEOUS GEL INJECTION; Drug
Lead sponsor: Tampa Bay Uveitis Center, LLC; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions: Laromustine (VNP40101M) and Ara-C; Drug
Lead sponsor: Viron Therapeutics Inc; Industry
Eligibility: 60 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer
Interventions: Family health history platform (MeTree); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 64 Years
Enrollment: 505 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Durham, North Carolina • Madison, Wisconsin

Conditions: Cancer
Interventions: High-flow Oxygen, Low-flow Oxygen, High-flow Air, Low-flow Air; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Chronic Low-back Pain (cLBP), High-Impact Chronic Pain (HICP)
Interventions: ENCompaSS (Education, Navigated Care, and Supported Self-Management) with VA Stepped Usual Care; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Leukemia, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions: Fludarabine phosphate, Busulfan, Total-Body Irradiation, Therapeutic Allogeneic Lymphocytes, Cyclophosphamide, Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Mycophenolate Mofetil, Laboratory Biomarker Analysis; Drug · Radiation · Biological + 2 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: Not listed
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Opioid-Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
Interventions: Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER), Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER); Drug
Lead sponsor: Member Companies of the Opioid PMR Consortium; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 61
States / cities: Foley, Alabama • Mobile, Alabama • Montgomery, Alabama + 49 more

Conditions: Obesity
Interventions: Ad libitum low carbohydrate diet, Ad libitum High Complex Carbohydrate Diet, Energy-restricted high complex carbohydrate diet; Other
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetes Mellitus, Ulcer, Diabetic Polyneuropathy
Interventions: personal dermal thermometer (DT), Device; Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Tucson, Georgia

Conditions: Underage Drinking, Drinking, Teen, Adolescent Alcohol Use
Interventions: e-CHECKUP TO GO (eCTG), e-Parent Intervention; Behavioral
Lead sponsor: Binghamton University; Other
Eligibility: 15 Years to 65 Years
Enrollment: 2,532 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Binghamton, New York

Conditions: Brain Tumor
Interventions: MRI; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma, T-Cell Large Granular Lymphocyte Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Rituximab, Total-Body Irradiation; Procedure · Drug · Other + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 3
States / cities: Rochester, Minnesota • Seattle, Washington

Conditions: Prostate Cancer
Interventions: Urinary ExoDx test, Transrectal ultrasound-guided prostate biopsy, Transperineal 12-core prostate biopsy; Device · Diagnostic Test
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 6
States / cities: New York, New York

Conditions: High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
Interventions: Bone Scan, Cabozantinib S-malate, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Surgical Procedure, X-Ray Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 40 Years
Enrollment: 1,122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 181
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 134 more

Conditions: Aged Macular Degeneration
Interventions: Omega 3, Olive Oil; Dietary Supplement · Other
Lead sponsor: Mid Atlantic Retina; Other
Eligibility: 20 Years to 49 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: 68-Ga RM2., 68-Ga PSMA11, PET/MRI; Drug · Device
Lead sponsor: Andrei Iagaru; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Chronic Stroke
Interventions: Treatment; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: BMTP-11; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: nivolumab, paclitaxel (PTX), nivolumab placebo, anthracycline, cyclophosphamide, Endocrine Therapy, Surgery; Biological · Drug · Other + 1 more
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 30
States / cities: Mobile, Alabama • Greenbrae, California • Whittier, California + 27 more

Conditions: Myelodysplastic Syndrome
Interventions: Decitabine, Vorinostat, Interleukin-2, Natural killer (NK) cells; Drug · Biological · Other
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Covid19, Corona Virus Infection, Autoimmune Diseases, Coagulation Disorder, Blood
Interventions: Narrow Band ultraviolet B-Band Light, non Narrow Band ultraviolet B-Band Light; Device
Lead sponsor: Cytokind, Inc.; Industry
Eligibility: 50 Years to 110 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Breast Cancer
Interventions: RealRisks Decision Aid; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 40 Years to 79 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia, Lymphoma, MDS
Interventions: Conditioning Regimen & GVHD Prophylaxis; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine

Impact of Family History and Decision Support on High-risk Cancer Screening

High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients

Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance

Comparing Non-Medicine Strategies for Improving Low Back Pain

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain

Energy Balance Weight Regulation Study

Dermal Thermometry and Self-Care of High Risk Diabetic Patients

Examining an Intervention to Reduce High School Drinking

High Resolution Magnetic Resonance Imaging in Patients With Brain Tumors

Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

ExosomeDx in MRI-negative Men With High PSA

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Omega-3-fatty Acids on Age-related Macular

HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

intenSive UpPer Extremity Recovery Program for Chronic Stroke (SUPER)

BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes

Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients

Decision Support for Chemoprevention

Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion